Lipfendra

The FDA has approved a new pill called Lipfendra, which clinical trials show can reduce LDL cholesterol levels by 60%. The drug targets LDL, the 'bad' type of cholesterol.

The FDA approved Merck's Lipfendra, a cholesterol-lowering pill that outperforms traditional statins and offers an easier alternative to injectable treatments. The approval could improve heart disease prevention, with AstraZeneca developing a competing pill.

The FDA approved Merck's Lipfendra, the first non-injectable pill targeting the PCSK9 protein to significantly reduce LDL cholesterol in high-risk patients. The drug offers a new option for those who need additional cholesterol-lowering beyond statins, with studies showing over 55% reductions in LDL levels.

The FDA has approved Lipfendra, a first-of-its-kind pill by Merck, to significantly reduce cholesterol in high-risk patients. This oral medication offers a cost-effective alternative to previously available expensive injectable treatments for lowering dangerous cholesterol levels.

The FDA approved Merck’s Lipfendra, the first non-injectable pill targeting PCSK9 to significantly reduce LDL cholesterol in patients not adequately controlled by statins. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under the FDA's fast-track program.

The FDA approved Merck's Lipfendra, the first non-injectable pill to block PCSK9 and significantly reduce LDL cholesterol in high-risk patients. Clinical trials showed over 55% LDL reduction in six months, with minimal side effects, positioning it as an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.

The FDA approved Merck's Lipfendra, the first non-injectable pill to significantly reduce LDL cholesterol in high-risk patients by blocking the PCSK9 protein. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under an accelerated FDA program led by Dr. Marty Makary. It offers an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.

Merck received FDA approval for Lipfendra, a PCSK9 inhibitor that serves as an alternative to statins for managing high LDL cholesterol. Statins, while widely prescribed, can cause side effects like muscle aches and may not sufficiently lower cholesterol levels for some patients.

The FDA approved enlicitide (brand name Lipfendra), a daily pill that lowers cholesterol levels more effectively than statins. The drug is produced by pharmaceutical company Merck.

Merck received FDA approval for Lipfendra, a once-daily cholesterol pill that reduced LDL cholesterol by up to 59% in late-stage trials, making it a competitor to existing injectable treatments.